Recent results from an experimental mice colitis model(dextran sulfate sodium salt (DSS)-induced colitis) reported WIN55,212-2acting as an anti-inflammatory drug with improved pathological changes,including decreased levels of TNFα and IL6 in blood and myeloperoxidase(MPO) activity in colon.25 Zymosan-inducededema studies were performed to estimate the anti-inflammatory profileof 34 (Figure 5) after s.c. administration at 100 μg/20 μL ofdose. This evidence concerns the gene MPO and colitis.